Paper Details

  1. Home
  2. Paper Details

Influenza virus resistance to neuraminidase inhibitors.

Author: AbedYacine, BoivinGuy, PizzornoAndrés, SamsonMélanie

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Antiviral agents are crucial for controlling seasonal influenza epidemics and may be essential during a pandemic. This article reviews the mechanism of action, pharmacokinetics, and clinical indications of neuraminidase inhibitors (NAIs), focusing on the emergence of drug resistance. Two NAIs, zanamivir and oseltamivir, are currently approved in the US. Peramivir and laninamivir are approved in other countries. The emergence of oseltamivir-resistant influenza viruses highlights the importance of monitoring drug susceptibilities. Future research should focus on understanding resistance mechanisms, developing novel antiviral targets, and evaluating combination therapies, especially for immunocompromised individuals.
Paper Details　
Original Abstract of the Article :
In addition to immunization programs, antiviral agents can play a major role for the control of seasonal influenza epidemics and may also provide prophylactic and therapeutic benefits during an eventual pandemic. The purpose of this article is to review the mechanism of action, pharmacokinetics and ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.antiviral.2013.03.014

データ提供：米国国立医学図書館（NLM）

Neuraminidase Inhibitors: Fighting Influenza, But Facing Resistance

Influenza, a contagious respiratory illness, can cause significant morbidity and mortality worldwide. Antiviral medications, including neuraminidase inhibitors (NAIs), play a crucial role in controlling influenza epidemics and pandemic outbreaks. However, the emergence of drug resistance poses a significant threat to the effectiveness of these medications.

The Challenge of Resistance: A Constant Battle Against Evolution

This article explores the mechanism of action, pharmacokinetics, and clinical indications of NAIs, with a particular focus on the emergence of antiviral drug resistance. The authors highlight the importance of continuous monitoring of antiviral drug susceptibilities to combat the evolution of resistant influenza viruses. Imagine a desert where the winds shift, constantly reshaping the landscape. Drug resistance in influenza is similar, where the virus adapts to the environment, creating new challenges for treatment.

Strategies for the Future: Combating Resistance

The authors discuss research priorities, including the development of novel compounds that target viral or host proteins, as well as the evaluation of combination therapies to improve treatment outcomes, particularly in vulnerable individuals. This research emphasizes the ongoing need for innovation and vigilance in the fight against influenza, particularly in light of the ever-present threat of drug resistance.

Dr. Camel's Conclusion

Influenza, a wily adversary, can be like a mirage in the desert, appearing as a source of relief but ultimately proving deceptive. This research highlights the importance of staying one step ahead, developing new strategies to combat the evolving threat of drug resistance, and ensuring the continued effectiveness of antiviral medications.
Date :
  1. Date Completed 2013-10-29
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

23523943

DOI: Digital Object Identifier

10.1016/j.antiviral.2013.03.014

Related Literature

Article Analysis
・Effects of zanamivir oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.